Honduras vs Senegal: Average cost of multi drug-resistant tuberculosis treatment
Honduras
3,743 constant 2022 US$
in 2024
Senegal
3,428 constant 2022 US$
in 2024
Honduras rank
11th
Senegal rank
12th
Average cost of multi drug-resistant tuberculosis treatment over time
- Honduras
- Senegal
How they compare
Honduras currently reports 3,743 constant 2022 US$ against 3,428 constant 2022 US$ in Senegal, a difference of 315 constant 2022 US$.
That makes Honduras's figure about 1.1 times Senegal's.
The two have swapped places 4 times across 6 shared years of data; in 2018 it was Honduras ahead.
Honduras ranks 11th and Senegal ranks 12th of 92 countries.
Senegal has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Honduras | Senegal | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,629 constant 2022 US$ | 2,555 constant 2022 US$ | 926 constant 2022 US$ | Senegal |
| 2020s | 2,225 constant 2022 US$ | 2,913 constant 2022 US$ | 687.5 constant 2022 US$ | Senegal |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Honduras or Senegal?
- Honduras, at 3,743 constant 2022 US$ against 3,428 constant 2022 US$ in Senegal as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Honduras and Senegal?
- 315 constant 2022 US$, with Honduras ahead.
- How many years of comparable data are there for Honduras and Senegal?
- 6 years are reported by both, from 2018 to 2024.
- How do Honduras and Senegal rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Honduras ranks 11th and Senegal ranks 12th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.